Skip to main content

China Shineway Pharmaceutical Group Limited (CSWYY)

New York Stock Exchange Healthcare Drug Manufacturers - Specialty & GenericView data quality →
69.5Fair

ValueMarkers Composite Index

Top 99%#535 of 44,722
Undervalued

99% below intrinsic value ($277)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.67
Low Risk
Altman
1.25
Distress
DCF Value
$277
Undervalued
ROIC
5.9%
Low
P/E
6.8
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

China Shineway Pharmaceutical Group Limited (CSWYY) — VMCI valuation read

The headline on China Shineway Pharmaceutical Group Limited (CSWYY) is a 70/100 VMCI score, set against a Healthcare sector median of 50. That 20-point above-median read reflects the five-pillar weighting and, for a mid-cap name, suggests a relative-value tailwind is in the data.

CSWYY insider activity report: 0 buys, 0 sells filed via Form 4 over the past 30 days. The next datable items are the 10-Q schedule and any 8-K-triggering events; both feed the VMCI Integrity pillar more than the price tape.

**Investor frame.** CSWYY trades at 25.0x earnings, 39% above the Healthcare median of 18.0x sets the value side. ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%) sets the quality side. Net debt to EBITDA of -0.6x leaves covenant headroom sets the risk side, the three lines a value buyer reads first on CSWYY.

CSWYY rose 1.0% over the trailing 7 days, with a -23.2% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.